Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25thGlobeNewsWire • Thursday
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic EncephalopathyPRNewsWire • 09/12/24
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101GlobeNewsWire • 08/08/23
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101GlobeNewsWire • 07/20/23
Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202GlobeNewsWire • 04/19/23
Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin ResearchGlobeNewsWire • 04/10/23
Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023GlobeNewsWire • 02/27/23
Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee RequirementsGlobeNewsWire • 02/08/23
Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price DeficiencyGlobeNewsWire • 01/27/23
Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D.GlobeNewsWire • 11/23/22
Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of DirectorsGlobeNewsWire • 09/07/22
Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet SyndromeGlobeNewsWire • 08/31/22